...
首页> 外文期刊>Genome Biology >Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy
【24h】

Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy

机译:结直肠癌免疫表型和反基因组的表征揭示了独特的肿瘤逃逸机制和免疫治疗的新目标

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: While large-scale cancer genomic projects are comprehensively characterizing the mutational spectrum of various cancers, so far little attention has been devoted to either define the antigenicity of these mutations or to characterize the immune responses they elicit. Here we present a strategy to characterize the immunophenotypes and the antigen-ome of human colorectal cancer. Results: We apply our strategy to a large colorectal cancer cohort (n = 598) and show that subpopulations of tumor-infiltrating lymphocytes are associated with distinct molecular phenotypes. The characterization of the antigenome shows that a large number of cancer-germline antigens are expressed in all patients. In contrast, neo-antigens are rarely shared between patients, indicating that cancer vaccination requires individualized strategy. Analysis of the genetic basis of the tumors reveals distinct tumor escape mechanisms for the patient subgroups. Hypermutated tumors are depleted of immunosuppressive cel s and show upregulation of immunoinhibitory molecules. Non-hypermutated tumors are enriched with immunosuppressive cells, and the expression of immunoinhibitors and MHC molecules is downregulated. Reconstruction of the interaction network of tumor-infiltrating lymphocytes and immunomodulatory molecules followed by a validation with 11 independent cohorts (n = 1,945) identifies BCMA as a novel druggable target. Finally, linear regression modeling identifies major determinants of tumor immunogenicity, which include well-characterized modulators as well as a novel candidate, CCR8, which is then tested in an orthologous immunodeficient mouse model. Conclusions: The immunophenotypes of the tumors and the cancer antigenome remain widely unexplored, and our findings represent a step toward the development of personalized cancer immunotherapies.
机译:背景:虽然大规模的癌症基因组计划全面地描述了各种癌症的突变谱,但迄今为止,很少有人关注定义这些突变的抗原性或表征它们引起的免疫反应。在这里,我们提出一种策略来表征人大肠癌的免疫表型和抗原组。结果:我们将策略应用于大型结直肠癌队列(n = 598),并显示肿瘤浸润淋巴细胞的亚群与不同的分子表型相关。反基因组的特征表明,在所有患者中都表达了大量的癌胚抗原。相反,新抗原很少在患者之间共享,这表明癌症疫苗接种需要个性化策略。肿瘤遗传基础的分析揭示了患者亚组独特的肿瘤逃逸机制。超突变的肿瘤耗尽了免疫抑制细胞,并显示出免疫抑制分子的上调。非超突变肿瘤富含免疫抑制细胞,免疫抑制剂和MHC分子的表达下调。重建肿瘤浸润淋巴细胞和免疫调节分子的相互作用网络,然后通过11个独立研究组(n = 1,945)的验证,将BCMA鉴定为新型可药物治疗靶标。最后,线性回归模型确定了肿瘤免疫原性的主要决定因素,其中包括特征明确的调节剂以及新型候选物CCR8,然后在直系同源免疫缺陷小鼠模型中对其进行测试。结论:肿瘤和癌基因组的免疫表型仍未得到广泛探索,我们的发现代表了朝着个性化癌症免疫疗法发展的一步。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号